ATS View
한국어

Samyang Biopharm KRX:0120G0KOSPI

삼양바이오팜 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days27
DART filings, 7 days0
Articles tracked31since Sep 11

In Q2 2026, Samyang Biopharm reported revenue of ₩35.9bn and operating profit of ₩746m. Samyang Biopharm (삼양바이오팜) appeared in 27 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 23 articles. The most common catalyst was tech & capacity (12). It was most often mentioned alongside Samyang Foods.

Samyang Biopharm quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩35.9bn–₩746m
margin 2.1%		₩1.3bn
Q1 2026₩31.2bn–₩1.4bn
margin 4.4%		₩2.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Samyang Biopharm top stories 2 weeks, by number of outlets

  1. 1
    삼양바이오팜·크로스포인트, 차세대 표적 유전자치료제 공동개발
    4 outlets · 4 articlesFirst report Oct 26 08:48 헤럴드경제Partnership
  2. 2
    삼양바이오팜 "크로스포인트와 스텔스바디–X-SENS 기반 유전자치료제 개발 MOU"
    4 outlets · 4 articlesFirst report Oct 26 08:42 한국경제
  3. 3
    삼양바이오팜, 크로스포인트와 차세대 항암제 개발
    2 outlets · 3 articlesFirst report Oct 26 10:06 이데일리
  4. 4
    크로스포인트-삼양바이오팜, 표적 선택적 유전자 신약 전달기술 공동개발
    2 outlets · 2 articlesFirst report Oct 26 08:30 히트뉴스Partnership
  5. 5
    크로스포인트·삼양바이오팜, siRNA 항암제 공동개발
    2 outlets · 2 articlesFirst report Oct 26 08:41 비즈워치Partnership
  6. 6
    삼양바이오팜-크로스포인트, 항암 유전자치료제 공동 개발 추진
    2 outlets · 2 articlesFirst report Oct 26 10:09 매일일보Partnership

Latest Samyang Biopharm news Korean headlines